Aclaris Therapeutics (ACRS) Total Current Liabilities (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Total Current Liabilities of $27.4 million for Q1 2026, up 27.22% year-over-year from $21.5 million in Q1 2025, and down 4.45% quarter-over-quarter from $28.6 million in Q4 2025.
Aclaris Therapeutics (ACRS) Total Current Liabilities (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Total Current Liabilities history runs 13 years deep, the most recent figure standing at $27.4 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.22% year-over-year to $27.4 million; the TTM figure through Mar 2026 stood at $27.4 million (up 27.22% YoY), while the FY2025 annual figure was $28.6 million, down 9.34% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $27.4 million, down from $28.6 million in the prior quarter.
- The five-year high for Total Current Liabilities was $31.6 million in Q4 2024, with the low at $15.7 million in Q2 2024.
- The 5-year median for Total Current Liabilities is $21.9 million (2022), against an average of $23.0 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities slumped 31.31% in 2024, then surged 71.15% in 2025.
- Aclaris Therapeutics' Total Current Liabilities stood at $21.9 million in 2022, then soared by 41.09% to $31.0 million in 2023, then increased by 2.08% to $31.6 million in 2024, then decreased by 9.34% to $28.6 million in 2025, then dropped by 4.45% to $27.4 million in 2026.
- Business Quant data shows ACRS's Total Current Liabilities at $27.4 million in Q1 2026, $28.6 million in Q4 2025, and $25.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 28.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.24 Mn |
| Mar 31, 2026 | 27.37 Mn |
| Dec 31, 2025 | 28.65 Mn |
| Sep 30, 2025 | 25.63 Mn |
| Jun 30, 2025 | 26.84 Mn |
| Mar 31, 2025 | 21.51 Mn |
| Dec 31, 2024 | 31.60 Mn |
| Sep 30, 2024 | 18.82 Mn |
| Jun 30, 2024 | 15.68 Mn |
| Mar 31, 2024 | 20.08 Mn |
| Dec 31, 2023 | 30.95 Mn |
| Sep 30, 2023 | 27.32 Mn |
| Jun 30, 2023 | 22.83 Mn |
| Mar 31, 2023 | 18.26 Mn |
| Dec 31, 2022 | 21.94 Mn |
| Sep 30, 2022 | 19.79 Mn |
| Jun 30, 2022 | 16.22 Mn |
| Mar 31, 2022 | 16.73 Mn |
| Dec 31, 2021 | 22.93 Mn |
| Sep 30, 2021 | 17.84 Mn |